Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2 Recruiting
153 enrolled
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Phase 2 Recruiting
33 enrolled
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 2 Recruiting
40 enrolled
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Phase 2 Recruiting
22 enrolled
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2 Recruiting
222 enrolled
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Phase 2 Recruiting
115 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma
Phase 2 Recruiting
15 enrolled
MK-2140-011
Phase 2 Recruiting
594 enrolled
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Phase 2 Recruiting
50 enrolled
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Phase 2 Recruiting
45 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Phase 2 Recruiting
372 enrolled
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
41 enrolled
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
Phase 2 Recruiting
28 enrolled
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Phase 2 Recruiting
30 enrolled
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Phase 2 Recruiting
256 enrolled
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
Phase 2 Recruiting
30 enrolled
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase 2 Recruiting
45 enrolled
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
Phase 2 Recruiting
20 enrolled
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Phase 2 Recruiting
65 enrolled
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 2 Recruiting
18 enrolled
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Recruiting
160 enrolled
TNT-HYPE
Phase 2 Recruiting
24 enrolled
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2 Recruiting
152 enrolled
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
42 enrolled
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Phase 2 Recruiting
54 enrolled
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
Phase 2 Recruiting
50 enrolled
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Phase 2 Recruiting
80 enrolled
BrECADD
Phase 2 Recruiting
48 enrolled
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Phase 2 Recruiting
51 enrolled
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Phase 2 Recruiting
20 enrolled
NeoTRACT
Phase 2 Recruiting
139 enrolled
NeoADAPT
Phase 2 Recruiting
30 enrolled
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
180 enrolled
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Phase 2 Recruiting
49 enrolled
TRUST
Phase 2 Recruiting
80 enrolled
TORNADO
Phase 2 Recruiting
66 enrolled
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Phase 2 Recruiting
148 enrolled
DOVE
Phase 2 Recruiting
198 enrolled
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Phase 2 Recruiting
50 enrolled
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Phase 2 Recruiting
30 enrolled
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Phase 2 Recruiting
71 enrolled
L-UteCIN
Phase 2 Recruiting
198 enrolled
RESPONSE
Phase 2 Recruiting
185 enrolled
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Phase 2 Recruiting
20 enrolled
PESETA
Phase 2 Recruiting
80 enrolled
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Phase 2 Recruiting
260 enrolled